{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:10:57Z","timestamp":1773810657763,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.neuropharm.2025.110775","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T16:07:09Z","timestamp":1763654829000},"page":"110775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Blockage of the peri-synaptic Schwann cell nicotinic \u03b17 receptor inhibitory drive increases the neuromuscular performance in rats with experimental autoimmune Myasthenia gravis: repurposing dipyridamole usage in myasthenics"],"prefix":"10.1016","volume":"284","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6397-2104","authenticated-orcid":false,"given":"Jos\u00e9 Bernardo","family":"Noronha-Matos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Sousa-Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2150-8121","authenticated-orcid":false,"given":"Beatriz","family":"Alves-Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9081-3184","authenticated-orcid":false,"given":"Liliana","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magda","family":"Moutinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2271-7075","authenticated-orcid":false,"given":"Rafael","family":"Neiva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6114-9189","authenticated-orcid":false,"given":"Paulo","family":"Correia-de-S\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neuropharm.2025.110775_bib1","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.STR.0000056527.34434.59","article-title":"Dipyridamole enhances NO\/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo\/ex vivo studies","volume":"34","author":"Aktas","year":"2003","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110775_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s43042-022-00354-1","article-title":"Dipyridamole and adenosinergic pathway in Covid-19: a juice or holy grail","volume":"23","author":"Al-Kuraishy","year":"2022","journal-title":"Egypt J Med Hum Genet"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110775_bib3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10557-021-07224-9","article-title":"Why not dipyridamole: a review of current guidelines and Re-evaluation of utility in the modern era","volume":"36","author":"Allahham","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110775_bib4","first-page":"749","article-title":"Train-of-four as an index of neuromuscular block in cats: changes induced by atropine","volume":"22","author":"Alves-do-Prado","year":"1989","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110775_bib5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110775_bib6","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.4049\/jimmunol.172.4.2697","article-title":"Breakdown of tolerance to a self-peptide of acetylcholine receptor \u03b1-Subunit induces experimental myasthenia gravis in rats","volume":"172","author":"Baggi","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.neuropharm.2025.110775_bib7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.phrs.2014.05.008","article-title":"Classical and pleiotropic actions of dipyridamole: not enough light to illuminate the dark tunnel?","volume":"87","author":"Balakumar","year":"2014","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110775_bib8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1189\/jlb.70.6.849","article-title":"Modes of action of Freund's adjuvants in experimental models of autoimmune diseases","volume":"70","author":"Billiau","year":"2001","journal-title":"J. Leukoc. Biol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110775_bib9","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/jm049363q","article-title":"Discovery and structure\u2212activity relationship of quinuclidine benzamides as agonists of \u03b17 nicotinic acetylcholine receptors","volume":"48","author":"Bodnar","year":"2005","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110775_bib10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00540-009-0790-z","article-title":"Presynaptic M1, M2, and A1 receptors play roles in tetanic fade induced by pancuronium or cisatracurium","volume":"23","author":"Bornia","year":"2009","journal-title":"J. Anesth."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110775_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1440-1681.2011.05476.x","article-title":"Presynaptic facilitatory adenosine A2A receptors mediate fade induced by neuromuscular relaxants that exhibit anticholinesterase activity","volume":"38","author":"Bornia","year":"2011","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110775_bib12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2025.110775_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.613070","article-title":"Efficacy and effect of inhaled adenosine treatment in hospitalized COVID-19 patients","volume":"12","author":"Caracciolo","year":"2021","journal-title":"Front. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2025.110775_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000494058","article-title":"Tetanic facilitation of neuromuscular transmission by adenosine A2A and muscarinic M1 receptors is dependent on the uptake of choline via high-affinity transporters","volume":"103","author":"Castell\u00e3o-Santana","year":"2019","journal-title":"Pharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110775_bib15","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/j.1476-5381.1991.tb09836.x","article-title":"Inhibitory and excitatory effects of adenosine receptor agonists on evoked transmitter release from phrenic nerve ending of the rat","volume":"103","author":"Correia-de-S\u00e1","year":"1991","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110775_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0306-4522(96)00028-0","article-title":"Adenosine uptake and deamination regulate tonic A2a receptor facilitation of evoked [3h]acetylcholine release from the rat motor nerve terminals","volume":"73","author":"Correia-de-S\u00e1","year":"1996","journal-title":"Neuroscience"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110775_bib17","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1152\/jn.1996.76.6.3910","article-title":"Presynaptic A1 inhibitory\/A2A facilitatory adenosine receptor activation balance depends on motor nerve stimulation paradigm at the rat hemidiaphragm","volume":"76","author":"Correia-de-S\u00e1","year":"1996","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2025.110775_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.toxicon.2012.10.014","article-title":"Bothropstoxin-I reduces evoked acetylcholine release from rat motor nerve terminals: radiochemical and real-time video-microscopy studies","volume":"61","author":"Correia-de-S\u00e1","year":"2013","journal-title":"Toxicon"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110775_bib19","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/jcp.22458","article-title":"On the role of subtype selective adenosine receptor agonists during proliferation and osteogenic differentiation of human primary bone marrow stromal cells","volume":"226","author":"Costa","year":"2011","journal-title":"J. Cell. Physiol."},{"issue":"16","key":"10.1016\/j.neuropharm.2025.110775_bib20","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1016\/S0021-9258(17)39364-X","article-title":"Conus geographus toxins that discriminate between neuronal and muscle sodium channels","volume":"260","author":"Cruz","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2025.110775_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110051","article-title":"Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: potential of pentoxifylline and dipyridamole","volume":"143","author":"DiNicolantonio","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"24","key":"10.1016\/j.neuropharm.2025.110775_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417614","article-title":"Elevated CD39+T-Regulatory cells and reduced levels of adenosine indicate a role for tolerogenic signals in the progression from moderate to severe COVID-19","volume":"24","author":"Elsaghir","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110775_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/syn.10211","article-title":"Blockade of neuronal facilitatory nicotinic receptors containing \u03b13\u03b22 subunits contribute to tetanic fade in the rat isolated diaphragm","volume":"49","author":"Faria","year":"2003","journal-title":"Synapse"},{"issue":"Pt 3","key":"10.1016\/j.neuropharm.2025.110775_bib24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1113\/jphysiol.2004.062349","article-title":"Hyperpolarized shifts in the voltage dependence of fast inactivation of Nav1.4 and Nav1.5 in a rat model of critical illness myopathy","volume":"559","author":"Filatov","year":"2004","journal-title":"J. Physiol."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110775_bib25","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1038\/nprot.2006.476","article-title":"Imaging synaptic vesicle exocytosis and endocytosis with FM dyes","volume":"1","author":"Gaffield","year":"2006","journal-title":"Nat. Protoc."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110775_bib26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.nmd.2020.12.004","article-title":"Physical training and exercise in myasthenia gravis","volume":"31","author":"Gilhus","year":"2021","journal-title":"Neuromuscul. Disord."},{"issue":"30","key":"10.1016\/j.neuropharm.2025.110775_bib27","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.neuropharm.2025.110775_bib28","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2025-0009","article-title":"Network connectivity, between-study heterogeneity and timepoint challenges in generalized myasthenia gravis: a feasibility assessment of indirect treatment comparisons","author":"Gilhus","year":"2025","journal-title":"J Comp Eff Res"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110775_bib29","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110775_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0049-3848(83)90356-0","article-title":"Mechanism of action of dipyridamole","volume":"4","author":"Harker","year":"1983","journal-title":"Thromb Res Suppl"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110775_bib31","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1476-5381.1991.tb12258.x","article-title":"Run-down of neuromuscular transmission during repetitive nerve activity by nicotinic antagonists is not due to desensitization of the postsynaptic receptor","volume":"102","author":"Hong","year":"1991","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110775_bib32","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110775_bib33","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110775_bib34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110775_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12030698","article-title":"Repurposing of the cardiovascular drug statin for the treatment of cancers: efficacy of statin-dipyridamole combination treatment in melanoma cell lines","volume":"12","author":"Irie","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.neuropharm.2025.110775_bib36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-2-44","article-title":"Myasthenia gravis","volume":"2","author":"Juel","year":"2007","journal-title":"Orphanet J. Rare Dis."},{"issue":"13","key":"10.1016\/j.neuropharm.2025.110775_bib37","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00018-016-2175-4","article-title":"Modulatory effects of alpha7 nAChRs on the immune system and its relevance for CNS disorders","volume":"73","author":"Kalkman","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110775_bib38","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/anae.14386","article-title":"Therapeutic doses of neostigmine, depolarising neuromuscular blockade and muscle weakness in awake volunteers: a double-blind, placebo-controlled, randomised volunteer study","volume":"73","author":"Kent","year":"2018","journal-title":"Anaesthesia"},{"issue":"16","key":"10.1016\/j.neuropharm.2025.110775_bib39","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/bph.15178","article-title":"ARRIVE 2.0 and the British journal of pharmacology: updated guidance for 2020","volume":"177","author":"Lilley","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110775_bib40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O","article-title":"Acetylcholine receptors and myasthenia","volume":"23","author":"Lindstrom","year":"2000","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110775_bib41","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.apsb.2020.04.008","article-title":"Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19","volume":"10","author":"Liu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110775_bib42","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1152\/japplphysiol.01266.2003","article-title":"Adverse effects of myasthenia gravis on rat phrenic diaphragm contractile performance","volume":"97","author":"van Lunteren","year":"2004","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.neuropharm.2025.110775_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.916156","article-title":"Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors","volume":"9","author":"Motloch","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.neuropharm.2025.110775_bib44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/ITT.S377056","article-title":"Novel immunotherapies for myasthenia gravis","volume":"12","author":"Nair","year":"2023","journal-title":"ImmunoTargets Ther."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110775_bib45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110775_bib46","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1471-4159.2011.07216.x","article-title":"Tetanic failure due to decreased endogenous adenosine A2A tonus operating neuronal Cav1 (L-type) influx in myasthenia gravis","volume":"117","author":"Noronha-Matos","year":"2011","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110775_bib47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/jnc.14975","article-title":"Nicotinic \u03b17 receptor-induced adenosine release from perisynaptic schwann cells controls acetylcholine spillover from motor endplates","volume":"154","author":"Noronha-Matos","year":"2020","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110775_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116649","article-title":"Differential participation of CaMKII\/ROCK and NOS pathways in the cholinergic inhibitory drive operated by nicotinic alpha7 receptors in perisynaptic schwann cells","volume":"231","author":"Noronha-Matos","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110775_bib49","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1046\/j.1460-9568.2002.02020.x","article-title":"Modulation by adenosine of both muscarinic M1-facilitation and M2-inhibition of [3H]-acetylcholine release from the rat motor nerve terminals","volume":"15","author":"Oliveira","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110775_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/460610","article-title":"Deficits in endogenous adenosine formation by Ecto-5\u2032-Nucleotidase\/CD73 impair neuromuscular transmission and immune competence in experimental autoimmune myasthenia gravis","author":"Oliveira","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.neuropharm.2025.110775_bib51","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.neuropharm.2014.09.004","article-title":"Amplification of neuromuscular transmission by methylprednisolone involves activation of presynaptic facilitatory adenosine A2A receptors and redistribution of synaptic vesicles","volume":"89","author":"Oliveira","year":"2015","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110775_bib52","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1124\/pharmrev.120.000097","article-title":"Therapeutic targeting of alpha7 nicotinic acetylcholine receptors","volume":"73","author":"Papke","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2025.110775_bib53","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ejphar.2013.11.001","article-title":"Paradoxical neostigmine-induced TOFfade: on the role of presynaptic cholinergic and adenosine receptors","volume":"723","author":"de Paula Ramos","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110775_bib54","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ejphar.2013.11.001","article-title":"Paradoxical neostigmine-induced TOFfade: on the role of presynaptic cholinergic and adenosine receptors","volume":"723","author":"de Paula Ramos","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110775_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073456","article-title":"Repurposing dipyridamole in niemann pick type C disease: a proof of concept study","volume":"23","author":"Pepponi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110775_bib56","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"4","author":"Percie du Sert","year":"2020","journal-title":"BMJ Open Sci"},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110775_bib57","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1440-1681.2011.05588.x","article-title":"Presynaptic muscarinic and adenosine receptors are involved in 2 Hz-induced train-of-four fade caused by antinicotinic neuromuscular relaxants in the rat","volume":"38","author":"Pereira","year":"2011","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110775_bib58","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1440-1681.2012.12004.x","article-title":"Adenosine A(2A) receptor antagonists are broad facilitators of antinicotinic neuromuscular blockade monitored either with 2 Hz train-of-four or 50 Hz tetanic stimuli","volume":"39","author":"Pereira","year":"2012","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110775_bib59","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1460-9568.2008.06113.x","article-title":"L-type calcium channels are involved in fast endocytosis at the mouse neuromuscular junction","volume":"27","author":"Perissinotti","year":"2008","journal-title":"Eur. J. Neurosci."},{"issue":"36","key":"10.1016\/j.neuropharm.2025.110775_bib60","doi-asserted-by":"crossref","first-page":"11870","DOI":"10.1523\/JNEUROSCI.0329-14.2014","article-title":"Schwann cells sense and control acetylcholine spillover at the neuromuscular junction by alpha7 nicotinic receptors and butyrylcholinesterase","volume":"34","author":"Petrov","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110775_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.811220","article-title":"Cholinesterases in tripartite neuromuscular synapse","volume":"14","author":"Petrov","year":"2021","journal-title":"Front. Mol. Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110775_bib62","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s11055-021-01108-z","article-title":"SARS-CoV-2 (COVID-19) as a predictor of neuroinflammation and neurodegeneration: potential treatment strategies","volume":"51","author":"Putilina","year":"2021","journal-title":"Neurosci. Behav. Physiol."},{"key":"10.1016\/j.neuropharm.2025.110775_bib63","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1113\/jphysiol.1987.sp016470","article-title":"On the role, inactivation and origin of endogenous adenosine at the frog neuromuscular junction","volume":"384","author":"Ribeiro","year":"1987","journal-title":"J. Physiol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110775_bib64","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110775_bib65","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1007\/s12035-023-03317-8","article-title":"Purinergic tuning of the tripartite neuromuscular synapse","volume":"60","author":"Sousa-Soares","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110775_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.676577","article-title":"Case report: can inhaled adenosine attenuate COVID-19?","volume":"12","author":"Spiess","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110775_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104615","article-title":"Dipyridamole as a new drug to prevent epstein-barr virus reactivation","volume":"172","author":"Thome","year":"2019","journal-title":"Antivir. Res."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110775_bib68","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nri2566","article-title":"Reflex control of immunity","volume":"9","author":"Tracey","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110775_bib69","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110775_bib70","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/BF00166975","article-title":"Muscarine receptors on the rat phrenic nerve, evidence for positive and negative muscarinic feedback mechanisms","volume":"335","author":"Wessler","year":"1987","journal-title":"N. Schmied. Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110775_bib71","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110775_bib72","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1021\/acs.chemrev.0c00644","article-title":"Toward a molecular basis of cellular nucleoside transport in humans","volume":"121","author":"Wright","year":"2021","journal-title":"Chem Rev"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110775_bib73","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1742-7843.2006.pto_516.x","article-title":"Mechanism of dipyridamole's action in inhibition of venous and arterial smooth muscle cell proliferation","volume":"99","author":"Zhuplatov","year":"2006","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110775_bib74","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/hep.26505","article-title":"Equilibrative nucleoside transporter (ENT)-1-dependent elevation of extracellular adenosine protects the liver during ischemia and reperfusion","volume":"58","author":"Zimmerman","year":"2013","journal-title":"Hepatology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:18:52Z","timestamp":1773807532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825004836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":74,"alternative-id":["S0028390825004836"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110775","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blockage of the peri-synaptic Schwann cell nicotinic \u03b17 receptor inhibitory drive increases the neuromuscular performance in rats with experimental autoimmune Myasthenia gravis: repurposing dipyridamole usage in myasthenics","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110775"}}